204 related articles for article (PubMed ID: 33860208)
1. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.
Wang V; Kuo TT; Huang EY; Ma KH; Chou YC; Fu ZY; Lai LW; Jung J; Choi HI; Choi DS; Li Y; Olson L; Greig NH; Hoffer BJ; Chen YH
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):858-869. PubMed ID: 33860208
[TBL] [Abstract][Full Text] [Related]
2. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Kuo TT; Chen YH; Wang V; Huang EY; Ma KH; Greig NH; Jung J; Choi HI; Olson L; Hoffer BJ; Tseng KY
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902115
[TBL] [Abstract][Full Text] [Related]
3. Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.
Wang V; Tseng KY; Kuo TT; Huang EY; Lan KL; Chen ZR; Ma KH; Greig NH; Jung J; Choi HI; Olson L; Hoffer BJ; Chen YH
J Biomed Sci; 2024 Apr; 31(1):38. PubMed ID: 38627765
[TBL] [Abstract][Full Text] [Related]
4. Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors.
Chen YH; Hsieh TH; Kuo TT; Kao JH; Ma KH; Huang EY; Chou YC; Olson L; Hoffer BJ
J Neurochem; 2019 Jul; 150(1):56-73. PubMed ID: 30933310
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.
Li Y; Vaughan KL; Tweedie D; Jung J; Kim HK; Choi HI; Kim DS; Mattison JA; Greig NH
Sci Rep; 2019 Nov; 9(1):17208. PubMed ID: 31748513
[TBL] [Abstract][Full Text] [Related]
6. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
[TBL] [Abstract][Full Text] [Related]
8. Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice.
Chen YH; Wang V; Huang EY; Chou YC; Kuo TT; Olson L; Hoffer BJ
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835787
[TBL] [Abstract][Full Text] [Related]
9. Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson's disease.
Lai JH; Chen KY; Wu JC; Olson L; Brené S; Huang CZ; Chen YH; Kang SJ; Ma KH; Hoffer BJ; Hsieh TH; Chiang YH
Brain Res; 2019 Oct; 1720():146301. PubMed ID: 31226324
[TBL] [Abstract][Full Text] [Related]
10. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.
Galter D; Pernold K; Yoshitake T; Lindqvist E; Hoffer B; Kehr J; Larsson NG; Olson L
Genes Brain Behav; 2010 Mar; 9(2):173-81. PubMed ID: 20002202
[TBL] [Abstract][Full Text] [Related]
11. Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease.
Li X; Redus L; Chen C; Martinez PA; Strong R; Li S; O'Connor JC
PLoS One; 2013; 8(8):e71341. PubMed ID: 23977020
[TBL] [Abstract][Full Text] [Related]
12. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
Elbassuoni EA; Ahmed RF
Neurochem Int; 2019 Dec; 131():104583. PubMed ID: 31654678
[TBL] [Abstract][Full Text] [Related]
14. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
15. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease.
Fifel K; Cooper HM
Neurobiol Dis; 2014 Nov; 71():359-69. PubMed ID: 25171792
[TBL] [Abstract][Full Text] [Related]
16. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
[TBL] [Abstract][Full Text] [Related]
17. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the early response and mechanism of treatment of Parkinson's disease with L-dopa using
Fa YH; Ni JQ; Wu XJ; Tan JQ; Wu YW
Exp Ther Med; 2016 Jan; 11(1):101-109. PubMed ID: 26889225
[TBL] [Abstract][Full Text] [Related]
19. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
20. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.
Good CH; Hoffman AF; Hoffer BJ; Chefer VI; Shippenberg TS; Bäckman CM; Larsson NG; Olson L; Gellhaar S; Galter D; Lupica CR
FASEB J; 2011 Apr; 25(4):1333-44. PubMed ID: 21233488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
